Sort by
Refine Your Search
-
are nurturing an environment for high-impact research and innovation in computer and data science, digital engineering, the advanced life sciences and medicine, and other tech fields. Partnership is what sets our
-
The successful candidate will join an interdisciplinary program integrating microbiology, synthetic biology, electrochemistry, and materials science. The program includes strong capabilities in engineering protein
-
and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research
-
experience in integrated evidence generation plan (IEGP) development, RWE generation, HEOR strategy and analytics, health technology assessment, value dossier development, and payer engagement. Year 2 consists
-
, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of
-
has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex
-
, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of
-
therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust
-
fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of
-
therapeutics utilizing CRISPR-based technologies. More specifically, we are employing a modular gene editing platform to create diverse in vivo and ex vivo therapeutics, spanning a range of disease indications